AdCare Health Systems third quarter 2013 revenues up 5 percent AdCare Wellness Systems, Inc Cipla Limited . , a respected long-term care provider, september 30 reported results for the third quarter and nine months ended, 2013. Financial Highlights Revenues up 5 percent to $55.9 million from $53.2 million in the year-ago period Adjusted EBITDAR from continuing functions was $5.4 million AdCare's financial results included a non-cash derivative gain of $2.0 million in comparison to a noncash derivative loss of $2.68 per share on the Business's 10.875 percent Series A Cumulative Redeemable Preferred Stock which was paid on September 30, on September 20 2013 to holders of record at the close of business, 2013 Subsequent to the quarter end, completed a open public offering of 500,000 shares of its 10.875 percent Series A Cumulative Redeemable Preferred Stock; $11.2 million net proceeds to be utilized for general corporate purposes; completed offering eliminates embedded derivative from monetary statements ‘The 3rd quarter is certainly our seasonally slowest one fourth and yet we shipped solid revenue growth from the year ago period for both the third one fourth and the first nine months of 2013,’ said AdCare's president and chief executive officer, Boyd P.
Adalimumab is approved for the treating moderate to severe rheumatoid arthritis in adults who do not respond to other treatments. Although DMARDs play an important part in arthritis treatment, only one, leflunomide, originated for rheumatoid arthritis treatment specifically. Methotrexate was developed as a tumor treatment.D., coauthor of a written publication on TNF blockers for arthritis, and clinical associate professor at the University of Texas-Southwestern Medical School in Dallas. For sufferers with long-standing disease, this review affirms combination therapy as the standard of care. Long-term efficacy and safety studies are needed. The reason for arthritis rheumatoid is unknown. The primary focus of the irritation can be in the synovium, the lining cells of the joint.